BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. International Immunopharmacology 2018;54:131-8. [DOI: 10.1016/j.intimp.2017.11.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Balighi K, Sakhi R, Daneshpazhooh M, Mahmoudi H, Teimourpour A, Tavakolpour S. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatologic Therapy 2018;31:e12671. [DOI: 10.1111/dth.12671] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 Hicham T, Chahnoun FZ, Hanafi T, Hjira N, Mohammed B. Pemphigus Vulgaris: A Clinical Study of 31 Cases (2004-2014) in Morocco. Dermatol Res Pract 2020;2020:8535109. [PMID: 32963520 DOI: 10.1155/2020/8535109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Kanokrungsee S, Anuntrangsee T, Tankunakorn J, Srisuwanwattana P, Suchonwanit P, Chanprapaph K. Rituximab Therapy for Treatment of Pemphigus in Southeast Asians. Drug Des Devel Ther 2021;15:1677-90. [PMID: 33911853 DOI: 10.2147/DDDT.S306046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Syed H, Ascoli C, Linssen CF, Vagts C, Iden T, Syed A, Kron J, Polly K, Perkins D, Finn PW, Novak R, Drent M, Baughman R, Sweiss NJ. Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:87-98. [PMID: 33093774 DOI: 10.36141/svdld.v37i2.9599] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Tavakolpour S, Mahmoudi H, Karami F, Elikaei Behjati S, Balighi K, Abbasi M, Salehi Farid A, Masoudi J, Balali M, Daneshpazhooh M, Modarressi MH. Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.14380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zeng FAP, Murrell DF. State-of-the-art review of human autoimmune blistering diseases (AIBD). Vet Dermatol 2021. [PMID: 34351020 DOI: 10.1111/vde.13008] [Reference Citation Analysis]
7 Bozca BC, Bilgiç A, Uzun S. Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus. J Dermatolog Treat 2021;:1-8. [PMID: 34027788 DOI: 10.1080/09546634.2021.1919288] [Reference Citation Analysis]
8 Mahmoudi H, Balighi K, Tavakolpour S, Daneshpazhooh M. Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases. Int Immunopharmacol 2019;71:40-2. [PMID: 30877872 DOI: 10.1016/j.intimp.2019.02.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
9 Bardazzi F, Loi C, Chessa Marco A, Di Altobrando A, Filippi F, Lacava R, Viviani F, Balestri R, Leuzzi M, Sacchelli L. Therapeutic approaches and targets for treatment of autoimmune bullous diseases. Dermatol Ther 2021;:e15032. [PMID: 34145701 DOI: 10.1111/dth.15032] [Reference Citation Analysis]
10 Mazloom E, Daneshpazhooh M, Shokouhi Shoormasti R, Balighi K, Mahmoudi H, Moradi Ketisari M, Eslami Faresani V, Ghandi N. Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study. Dermatol Ther 2020;33:e14407. [PMID: 33051954 DOI: 10.1111/dth.14407] [Reference Citation Analysis]
11 Balighi K, Mahmoudi H, Tavakolpour S, Daneshpazhooh M. Coexistence of oral lichen planus and pemphigus vulgaris. Clin Oral Invest 2018;22:2953-5. [DOI: 10.1007/s00784-018-2619-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Porro AM, Seque CA, Ferreira MCC, Enokihara MMSES. Pemphigus vulgaris. An Bras Dermatol 2019;94:264-78. [PMID: 31365654 DOI: 10.1590/abd1806-4841.20199011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
13 Lima RB, Manhães MB, de Souza Felix M, Gonçalves MLC. Septic shock in a refractory pemphigus vulgaris patient after rituximab therapy. Dermatol Ther 2021;34:e14725. [PMID: 33377269 DOI: 10.1111/dth.14725] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Faraji H, Daneshpazhooh M, Ehsani AH, Mahmoudi H, Tavakolpour S, Aryanian Z, Aslani S, Khodaveisi H, Balighi K. Evaluating the risk-to-benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: A retrospective study with 494 patients. Dermatol Ther 2021;:e15257. [PMID: 34890103 DOI: 10.1111/dth.15257] [Reference Citation Analysis]
15 Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. An Bras Dermatol 2019;94:20-32. [PMID: 31166407 DOI: 10.1590/abd1806-4841.2019940206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
16 Mahmoudi H, Ebrahimi E, Daneshpazhooh M, Balighi K, Mirzazadeh A, Elikaei Behjati S, Tavakolpour S. Single-nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine. Int J Immunogenet 2020;47:41-9. [PMID: 31342641 DOI: 10.1111/iji.12451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
17 Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, Bergman R, Bernard P, Borradori L, Caproni M, Caux F, Cianchini G, Daneshpazhooh M, De D, Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Guenther C, Hofmann S, Ioannides D, Kowalewski C, Ludwig R, Lim Y, Marinovic B, Marzano A, Mascaró J, Mimouni D, Murrell D, Pincelli C, Squarcioni C, Sárdy M, Setterfield J, Sprecher E, Vassileva S, Wozniak K, Yayli S, Zambruno G, Zillikens D, Hertl M, Schmidt E. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020;34:1900-13. [DOI: 10.1111/jdv.16752] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
18 Tavakolpour S, Mahmoudi H, Mirzazadeh A, Balighi K, Darabi-monadi S, Hatami S, Ghasemiadl M, Daneshpazhooh M. Pathogenic and protective roles of cytokines in pemphigus: A systematic review. Cytokine 2020;129:155026. [DOI: 10.1016/j.cyto.2020.155026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
19 Bilgic A, Murrell DF. What is novel in the clinical management of pemphigus. Expert Review of Clinical Pharmacology 2019;12:973-80. [DOI: 10.1080/17512433.2019.1670059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
20 Amber KT, Maglie R, Solimani F, Eming R, Hertl M. Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs 2018;78:1527-48. [PMID: 30238396 DOI: 10.1007/s40265-018-0976-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
21 Frampton JE. Rituximab: A Review in Pemphigus Vulgaris. Am J Clin Dermatol 2020;21:149-56. [PMID: 31838645 DOI: 10.1007/s40257-019-00497-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
22 Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. Clin Dermatol 2020;38:384-96. [PMID: 32563354 DOI: 10.1016/j.clindermatol.2019.07.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Balighi K, Daneshpazhooh M, Akbari Z, Tavakolpour S, Azimi P, Azizpour A. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. Journal of Dermatological Treatment 2018;30:346-9. [DOI: 10.1080/09546634.2018.1509049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fortuna G, Calabria E, Aria M, Giudice A, Mignogna MD. Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant. Biomolecules 2021;11:1634. [PMID: 34827631 DOI: 10.3390/biom11111634] [Reference Citation Analysis]
25 Pires CAA, Einecke YS, Pereira NG, Costa CCC, Cunha ACDS, Moreira AG, Rodrigues FDN, Xavier MB. Therapeutic outcomes of pemphigus in a referral service in Northern Brazil: a retrospective study of 32 patients. J Dermatolog Treat 2021;32:1031-4. [PMID: 31935147 DOI: 10.1080/09546634.2020.1714540] [Reference Citation Analysis]
26 Balighi K, Daneshpazhooh M, Mahmoudi H, Badakhsh M, Teimourpour A, Ehsani AH, Azizpour A, Akbari Z, Mahdavinia M, Ghasemiadl M, Tavakolpour S. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? Arch Dermatol Res 2019;311:63-9. [DOI: 10.1007/s00403-018-1881-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
27 Yoo DS, Kim JH, Kim SC. Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab. JAAD Case Rep 2020;6:83-5. [PMID: 31970283 DOI: 10.1016/j.jdcr.2019.10.017] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tavakolpour S, Aryanian Z, Seirafianpour F, Dodangeh M, Etesami I, Daneshpazhooh M, Balighi K, Mahmoudi H, Goodarzi A. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. Immunopharmacol Immunotoxicol 2021;:1-12. [PMID: 34287098 DOI: 10.1080/08923973.2021.1953063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Fortuna G, Calabria E, Ruoppo E, Adamo D, Aria M, Amato M, Mignogna MD. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris. J Oral Pathol Med 2019;49:91-5. [DOI: 10.1111/jop.12951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Nili A, Tavakolpour S, Mahmoudi H, Noormohammadpour P, Balighi K, Daneshpazhooh M. Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases. Immunopharmacology and Immunotoxicology 2020;42:56-8. [DOI: 10.1080/08923973.2020.1717526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
31 Tavakolpour S. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. Dermatologic Therapy 2018;31:e12696. [DOI: 10.1111/dth.12696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
32 Daneshpazhooh M, Balighi K, Mahmoudi H, Tavakolpour S, Abedini R, Soori T, Ehsani A, Ghiasi M, Noormohammadpour P, Ghandi N, Lajevardi V, Sadeghinia A, Nasimi M, Azizpour A, Chams‐davatchi C. Iranian guideline for rituximab therapy in pemphigus patients. Dermatologic Therapy 2019;32. [DOI: 10.1111/dth.13016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
33 Abedini R, Mahmoudi H, Kordestani S, Habib FN, Abyaneh M, Rahemi H. Comparison of topical nanocolloidal silver formulation use with eosin 2% solution in management of hard-to-heal ulcers in patients with pemphigus vulgaris. J Wound Care 2020;29:664-8. [PMID: 33175623 DOI: 10.12968/jowc.2020.29.11.664] [Reference Citation Analysis]
34 Perifani V, Dalamaga M, Theodoropoulos K, Theotokoglou S, Syrmali A, Loumou P, Papadavid E. Real world evidence: Patients with refractory pemphigus treated with Rituximab. Metabol Open 2021;12:100142. [PMID: 34746731 DOI: 10.1016/j.metop.2021.100142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kraft M, Worm M. Pemphigus Foliaceus-Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report. Front Med (Lausanne) 2018;5:315. [PMID: 30474029 DOI: 10.3389/fmed.2018.00315] [Reference Citation Analysis]
36 Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, Daneshpazhooh M. Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab. Int J Womens Dermatol 2019;5:372-7. [PMID: 31909160 DOI: 10.1016/j.ijwd.2019.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
37 Ghaedi F, Etesami I, Aryanian Z, Kalantari Y, Goodarzi A, Teymourpour A, Tavakolpour S, Mahmoudi H, Daneshpazhooh M. Drug-induced pemphigus: A systematic review of 170 patients. Int Immunopharmacol 2021;92:107299. [PMID: 33418246 DOI: 10.1016/j.intimp.2020.107299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
38 Toosi R, Mahmoudi H, Balighi K, Teimourpour A, Alaeen H, Shaghaghi M, Abedini R, Daneshpazhooh M. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study. Journal of Dermatological Treatment 2021;32:33-40. [DOI: 10.1080/09546634.2019.1617831] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
39 Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol 2019;10:1418. [PMID: 31293582 DOI: 10.3389/fimmu.2019.01418] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
40 Kridin K, Ahmed AR. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. Expert Opin Biol Ther 2021;21:443-54. [PMID: 33455475 DOI: 10.1080/14712598.2021.1874915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Mahmoudi H, Tavakolpour S, Balighi K, Farid AS, Nili A, Jan D, Daneshpazhooh M. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther 2021;34:e14633. [PMID: 33280226 DOI: 10.1111/dth.14633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]